Marek Honczarenko - 25 Feb 2026 Form 4 Insider Report for Keenova Therapeutics plc

Role
EVP, Chief Scientific Officer
Signature
/s/ Mark Tyndall, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
25 Feb 2026
Net transactions value
$0
Form type
4
Filing time
26 Feb 2026, 21:13:02 UTC
Previous filing
01 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Honczarenko Marek EVP, Chief Scientific Officer 440 ROUTE 22 EAST, SUITE 302, BRIDGEWATER /s/ Mark Tyndall, Attorney-in-Fact 26 Feb 2026 0002089105

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction Restricted Stock Units Award $0 +58,434 $0.000000 58,434 25 Feb 2026 Ordinary Shares 58,434 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Upon vesting, each restricted stock unit ("RSU") will be settled in ordinary shares of the Issuer at one share per RSU.
F2 The RSUs will vest ratably on each of the first three anniversaries of February 25, 2027.

Remarks:

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.